There’s plenty to like about the lower direct-to-consumer prices the White House negotiated with Eli Lilly and Novo Nordisk. There are also caveats and some unanswered questions.
The deal involves Eli Lilly, which makes Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy. The drugs, known as GLP-1 medications, now cost as much as $1350 a month. Under the ...
Oral GLP-1 weight loss pills could replace injections by March 2026 at $150 monthly, Medicare chief Dr. Mehmet Oz predicted ...
1d
The next-generation weight loss drug that’s ‘as effective as Mounjaro – WITHOUT Ozempic side effect’
A NEW weight loss drug may offer a tempting alternative to popular GLP-1 drugs like Ozempic and Wegovy. The once-weekly ...
The results were published in The New England Journal of Medicine as part of the OASIS 4 phase 3 trial. The findings show ...
TEENAGE boys aren’t famous for expressing their feelings. But as my son Jeremiah sweeps me up into a hug and thanks me, I ...
Donald Trump hailed his deal to slash the price of blockbuster weight loss drugs as a game changer. But major gaps in the ...
Dr. Oz estimated Americans could lose "135 billion pounds" by the midterm elections next year. The administrator of the ...
The White House is expected to announce a deal for lower prices of obesity drugs from Novo Nordisk and Eli Lilly on Thursday ...
Mounjaro, the breakthrough obesity and diabetes drug from Eli Lilly and Company, has become India’s highest-selling ...
“It’s a triumph for American patients that will save lives and improve the health of millions and millions of Americans,” ...
Even after Trump’s new deal, obesity drugs are still too expensive.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback